Phathom Pharmaceuticals, Inc. PHAT Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s retained earnings?
- Phathom Pharmaceuticals, Inc. (PHAT) reported retained earnings of -$1.51B in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s retained earnings decreased by 11.6% year-over-year, from -$1.36B to -$1.51B.
- What is the long-term trend for Phathom Pharmaceuticals, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Phathom Pharmaceuticals, Inc.'s retained earnings has grown at a 30.9% compound annual growth rate (CAGR), from -$385.49M to -$1.48B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.